Thrombosis News and Research

Latest Thrombosis News and Research

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study.

11 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Researchers identify central switch by which HDL controls inflammatory response

High-density lipoprotein, known colloquially as "good cholesterol", protects against dangerous deposits in the arteries. An important function of HDL is its anti-inflammatory properties. An international research team at the Institute of Innate Immunity at the University Hospital of Bonn and the LIMES Institute at the University of Bonn has identified a central switch by which HDL controls the inflammatory response. The results are presented in the current issue of "Nature Immunology".

9 Dec 2013

WHO releases new report on spinal cord injury

As many as 500 000 people suffer a spinal cord injury each year. People with spinal cord injuries are 2 to 5 times more likely to die prematurely, with worse survival rates in low- and middle-income countries. The new WHO report, "International perspectives on spinal cord injuries", summarizes the best available evidence on the causes, prevention, care and lived experience of people with spinal cord injury.

2 Dec 2013

Pivotal Therapeutics reports financial results for Q3 2013

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies announced its third quarter financial results and operational highlights for the three and nine months ended September 30, 2013.

30 Nov 2013

Research: Human neural stem cells could improve blood flow in critical limb ischemia

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

27 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Vasculitis damage swift, accumulating

Study findings reveal the significant burden of disease among patients with antineutrophil-cytoplasm antibody associated vasculitis, with many individuals showing irreversible damage shortly after diagnosis.

22 Nov 2013

Sinai Hospital reports results from Phase 2a trial of apo A-I infusion therapy CSL112

Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.

22 Nov 2013

Elsevier launches two new open access journals in cardiology journals series

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of two new open access journals in its cardiology journals series: International Journal of Cardiology-Heart & Vessels and International Journal of Cardiology-Metabolic & Endocrine.

20 Nov 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.

18 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Researchers identify link between narrowed heart valves and special lipoprotein in blood

Researchers at the University of Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link between narrowed heart valves and a special lipoprotein in the blood. In the long term, the research may well help to prevent valvular heart disease.

13 Nov 2013

‘Pioneering’ non-invasive coronary plaque imaging revealed

Combined 18F-sodium fluoride positron emission tomography–computed tomography allows physicians to visualize high-risk or ruptured coronary atherosclerotic plaques in patients with myocardial infarction or stable angina, research shows.

12 Nov 2013

Rice U. researchers link von Willebrand factor to heart-valve calcium deposits

Heart valves calcify over time, and Rice University scientists are beginning to understand why. The Rice lab of bioengineer Jane Grande-Allen found through studies of pigs' heart valves that age plays a critical role in the valves' progressive hardening, and the problem may be due to the infiltration of a protein known as von Willebrand factor.

8 Nov 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Researchers explore strategies that would optimize fresher blood for patients

Although clinical evidence is lacking on the relationship between the storage time of red blood cells and outcomes in transfused patients, the authors of a review article in the November 2013 issue of The Annals of Thoracic Surgery are advocating for a modernized blood management system—similar to inventory management systems seen in the retail sector—to potentially reduce patient complications.

31 Oct 2013

Thrombosis News and Research

Latest Thrombosis News and Research

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Researchers identify central switch by which HDL controls inflammatory response

WHO releases new report on spinal cord injury

Pivotal Therapeutics reports financial results for Q3 2013

Research: Human neural stem cells could improve blood flow in critical limb ischemia

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Vasculitis damage swift, accumulating

Sinai Hospital reports results from Phase 2a trial of apo A-I infusion therapy CSL112

Elsevier launches two new open access journals in cardiology journals series

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Researchers identify link between narrowed heart valves and special lipoprotein in blood

‘Pioneering’ non-invasive coronary plaque imaging revealed

Rice U. researchers link von Willebrand factor to heart-valve calcium deposits

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Researchers explore strategies that would optimize fresher blood for patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in